Clinical trial
Safety and Efficacy of Vildagliptin vs. Thiazolidinedione as add-on Therapy to…
NCT00396227 · Novartis Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00396227 |
|---|---|
| Title | Safety and Efficacy of Vildagliptin vs. Thiazolidinedione as add-on Therapy to Metformin in Patients With Type 2 Diabetes Not Controlled With Metformin Alone |
| Official title | A Multi-center, Randomized, Open-label, Active Controlled, Parallel Arm Study to Compare the Efficacy of 12 Weeks of Treatment With Vildagliptin 100 mg, qd to Thiazolidinedione (TZD) as add-on Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy in a… |
| Lead sponsor | Novartis Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Diabetes Mellitus, Type 2 |
| Intervention type | Drug |
| Interventions | vildagliptin, thiazolidinedione (TZD) |
| Enrollment | 2,665 |
| Start date | Oct 1, 2006 |
| Primary completion | Oct 1, 2007 |
| First posted | Nov 6, 2006 |
| Last update posted | Nov 18, 2016 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: